Newsroom

OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey at ASCO GU

- OnQuality will present an update on its NOVA-II Phase 2 clinical trial investigating OQL011, a proprietary ointment designed to treat...

Feb 14, 2022

Full Title: OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for New Cancer Therapy-Associated Diarrhea...

Jan 19, 2022

Therapy Induced Skin Toxicity that Met Expectations - Part 1 of the Phase 2 NOVA-II clinical trial evaluating OQL011 met the company's...

Jan 4, 2022

- Top-line readout of clinical study results anticipated by the end of 2021 SEATTLE, Sept. 7, 2021 /PRNewswire/ -- OnQuality...

Sep 7, 2021

SEATTLE, June 9, 2021 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted cancer supportive care company developing...

Jun 9, 2021

OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011 at the 2021 ASCO and MASCC/ISOO Annual Meetings SEATTLE, May 19,...

May 19, 2021

SEATTLE and SHANGHAI—March 31, 2021. OnQuality Pharmaceuticals LLC ("OnQuality"), a targeted cancer supportive care company developing me...

Mar 31, 2021

Seattle, WA—August 14, 2020. OnQuality Pharmaceuticals (USA) LLC, dedicated to the discovery and development of therapies to improve qua...

Aug 14, 2020

Shanghai, China—Oct. 28th, 2019. OnQuality Pharmaceuticals Ltd., a start-up pharmaceutical company focusing on mitigating on-target toxic...

Oct 28, 2019

Shanghai, China—May 24th, 2019. OnQuality Pharmaceuticals Ltd., today announced the U.S. Food and Drug Administration (FDA) clearance of...

May 24, 2019